Although median PFS and median OS were quite modest (3.6 and 10.8 months respectively), pathological review of tumor samples showed that a significant increase in CD8+ T cells infiltrates in 60% of cases and this change was associated with improved outcome, suggesting a synergism in shaping the TME of this drug combination. The gene discussed is CD8A; the disease is neoplasm.